Core Viewpoint - The China Automotive Technology Research Center has launched a year-round ice and snow testing base for intelligent connected new energy vehicles in Hulunbuir, Inner Mongolia, which will be the largest and most advanced facility of its kind globally [1][2]. Group 1: Project Overview - The project is being constructed with an investment of 1.2 billion yuan and will cover approximately 1,000 acres [2]. - The base will feature five functional areas, including testing for the three electric systems (battery, motor, and electric drive), chassis system calibration, snow scene simulation testing, dynamic testing grounds, and flying car testing [2]. Group 2: Industry Implications - The establishment of the testing base is a response to the new demands for stable testing conditions and controllable intelligent driving scenarios in cold regions, addressing the bottleneck in the development cycle of new vehicle models [1][2]. - The project aims to enhance the quality of intelligent connected new energy vehicles, marking a transition from scale expansion to quality improvement in the industry [2]. Group 3: Regional Significance - Hulunbuir is positioned as a core testing base for cold regions in northern China, leveraging its unique environmental advantages for extreme condition testing [2]. - The new facility will fill the gap in year-round testing capabilities for ice and snow conditions in China, promoting a healthy ecosystem of testing services, technology research, and industrial application [2].

Group 1 - The State Intellectual Property Office of China has granted a patent for a method of preparing L96 side-chain compounds to Suzhou Fushilai Pharmaceutical Co., Ltd. and Suzhou Kuntai Biotechnology Co., Ltd., with the patent announcement number CN118993970B and application date of May 2023 [1] - Suzhou Fushilai Pharmaceutical Co., Ltd. was established in 2000, located in Suzhou, and primarily engages in the manufacturing of chemical raw materials and products, with a registered capital of 91.67 million RMB [1] - Suzhou Fushilai has invested in 4 companies, participated in 57 bidding projects, holds 20 trademark registrations, 108 patents, and possesses 82 administrative licenses [1] - Suzhou Kuntai Biotechnology Co., Ltd. was founded in 2022, also located in Suzhou, focusing on research and experimental development, with a registered capital of 50 million RMB [1] - Suzhou Kuntai has participated in 6 bidding projects, holds 4 patents, and has 4 administrative licenses [1]

Group 1 - The core point of the article is that Fujilai (301258) has reported a total of 9,810 shareholders as of December 19, 2025 [1]

Group 1 - The core point of the article is that Fujilai (301258) has reported a total of 9,811 shareholders as of December 10, 2025 [1]

Group 1 - The new national standard for electric bicycles has been implemented since December, enforcing a speed limit of 25 km/h that cannot be unlocked [1] - Manufacturers face strict penalties for violating the new regulations, leading to the complete closure of speed unlocking channels [1] - Multiple electric bicycle brands confirm that the speed limit is secured by a triple anti-tampering mechanism, making it impossible to unlock [1] Group 2 - The new standard includes built-in Beidou positioning systems in electric bicycles to monitor speed, replacing previous brand-specific navigation systems [1] - Industry insiders indicate that consumers needing higher speeds must switch to electric motorcycles, which require a license and registration [1] - Due to price increases in electric bicycles, some users may consider directly purchasing electric motorcycles instead [1]

证券日报网讯 12月9日晚间，富士莱发布公告称，公司于近日收到国家药品监督管理局签发的关于硫辛 酸片的《药品注册证书》。 （文章来源：证券日报） ...

Group 1 - Wanma Technology has been pre-awarded a total of 59.9434 million yuan for multiple State Grid projects, which accounts for 14.49% of its latest audited main business revenue [1] - Tianen Kang's subsidiary received a drug registration certificate for Methimazole tablets, a medication used for hyperthyroidism [2] - Taijing Technology invested 10 million yuan to establish a special fund focused on high-speed network communication chips [3] Group 2 - Youyou Foods plans to use 10 million yuan of its own funds to purchase principal-protected financial products with an expected annual yield of 0.5%-5.0% [4] - Yangfan New Materials announced the release of detention measures against its controlling shareholder, allowing him to resume his duties [5] - Xianju Pharmaceutical received approval for a supplementary application for Nicardipine injection, a calcium channel blocker used for acute hypertension [6] Group 3 - Jingu Co. plans to repurchase shares worth 30-60 million yuan for employee stock ownership plans or equity incentives [7] - Double Tower Foods' Thai subsidiary has completed the construction of its production line and is in the initial production phase [8] - Tongyi Zhong intends to invest approximately 198 million yuan in a project for the industrialization of ultra-high molecular weight polyethylene fibers [9][10] Group 4 - Zhangyue Technology received a dividend of 4.99 million yuan from its stake in Dianzhong Technology, which represents 10.12% of its audited net profit for 2024 [11] - Sihua Electronics announced the resignation of its general manager due to job transfer, with the current manager continuing until a new one is appointed [12] - Jiutian Pharmaceutical's new drug JMHT06 has received approval for clinical trials for acute gouty arthritis [13] Group 5 - Anlian Ruishi has established a joint venture for embodied intelligent robots with a registered capital of 20 million yuan [14] - Kelin Electric's application for a private placement has been accepted by the Shanghai Stock Exchange [15] - Guoyao Modern's subsidiary has received approval for the listing of Agomelatine raw materials, used in antidepressant synthesis [16] Group 6 - Xintiandi's application for the listing of Ferrous Fumarate raw materials has been approved, which is used for treating iron deficiency anemia [17] - ST Weihai, as the leading party, won a bid for a smart agriculture project worth 652 million yuan, accounting for 26.27% of its 2024 audited revenue [18] - Tian Youwei plans to purchase 100% of Krämer Automotive Systems for 1 million euros [19] Group 7 - Guangdong Yuedian A's subsidiary has successfully put into operation the third unit of its Dapu Power Plant project [20] - China Life's total premium exceeded 700 billion yuan as of November 30, 2025 [21] - Shoukai Co. achieved a total signed amount of 15.988 billion yuan in the first 11 months of 2025 [22] Group 8 - Kehua Bio's subsidiary has obtained a medical device registration certificate for an automatic chemiluminescence immunoassay analyzer [23] - Chengyi Pharmaceutical received a drug registration certificate for Torasemide tablets, which have passed the consistency evaluation [24] - Chongqing Construction won a bid for a municipal engineering project worth approximately 1.714 billion yuan [25] Group 9 - Hanjian Heshan signed a procurement contract for pipes worth 388 million yuan [26] - Jiuzhou Pharmaceutical plans to use up to 1 billion yuan of idle raised funds for cash management [27] - Xinwufeng reported an 80.97% year-on-year increase in pig sales in November 2025 [28] Group 10 - Luoniushan reported a 13.57% year-on-year increase in pig sales revenue in November 2025 [29] - Fushilai received a drug registration certificate for Alpha-Lipoic Acid tablets, used for diabetic neuropathy [30] - Dizhe Pharmaceutical presented research data on two innovative drugs at the 67th American Society of Hematology conference [31] - David Medical's subsidiary received two medical device registration certificates for single-use gastric tubes and electronic ureteral endoscope catheters [32]

智通财经APP讯，富士莱(301258.SZ)公告，公司近日收到国家药品监督管理局签发的关于硫辛酸片的 《药品注册证书》。硫辛酸片适应症为：用于糖尿病周围神经病变引起的感觉异常。 ...

每经AI快讯，富士莱（SZ 301258，收盘价：32.62元）12月9日晚间发布公告称，苏州富士莱医药股份 有限公司于近日收到国家药品监督管理局签发的关于硫辛酸片的《药品注册证书》。产品名称为"硫辛 酸片"。 每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 （记者 王瀚黎） 2024年1至12月份，富士莱的营业收入构成为：医药占比99.19%，其他业务占比0.81%。 截至发稿，富士莱市值为30亿元。 ...

富士莱（301258）(301258.SZ)公告，公司近日收到国家药品监督管理局签发的关于硫辛酸片的《药品 注册证书》。硫辛酸片适应症为：用于糖尿病周围神经病变引起的感觉异常。 ...